Current status and future direction in the management of malignant melanoma

Melanoma Research

Volumn 27, Issue 5, 2017, Pages 403-410

  Gladfelter, Patrick ^a   Darwish, Noureldien H E ^a,b   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

BRAF; CTLA 4; MEK inhibitor; Melanoma; Nanoparticle; Photodynamic therapy; Programmed cell death 1 receptor

Indexed keywords

AXITINIB; B RAF KINASE INHIBITOR; BEVACIZUMAB; CANCER VACCINE; DACARBAZINE; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; NANOPARTICLE; PEGINTERFERON ALPHA; PEMBROLIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RNA VACCINE;

ABLATION THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RESEARCH; CANCER THERAPY; HUMAN; MELANOMA; METASTATIC MELANOMA; NANOTECHNOLOGY; NONHUMAN; ONCOGENE N RAS; PERSONALIZED MEDICINE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; ANIMAL; FORECASTING; PATHOLOGY; SKIN TUMOR;

ANIMALS; FORECASTING; HUMANS; MELANOMA; PRECISION MEDICINE; SKIN NEOPLASMS;

EID: 85032373537     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000379     Document Type: Review

References (88)

1. American Cancer Society. Cancer Facts and Figures 2016. Available at: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf. [Accessed 13 October 2016].
2. Tronnier M, Mitteldorf C. Treating advanced melanoma: current insights and opportunities. Cancer Manag Res 2014; 6: 349-356.
3. Olszanski AJ. Current and future roles of targeted therapy and immunotherapy in advanced melanoma. J Manag Care Spec Pharm 2014; 20: 346-356.
4. International Agency for Research on Cancer. Pathology and genetics of tumours of the skin, world health organization classification of tumours. Available at: http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb6/. [Accessed 13 March 2017].
5. Weyers W, Euler M, Diaz-Cascajo C, Schill WB, Bonczkowitz M. Classification of cutaneous malignant melanoma: a reassessment of histopathologic criteria for the distinction of different types. Cancer 1999; 86: 288-299.
6. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline: update 2016. Eur J Cancer 2016; 63: 201-217.
7. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician-gls/f-guidelines.asp. [Accessed 13 March 2017].
9. Li J, Wang Y, Liang R, An X, Wang K, Shen G, et al. Recent advances in targeted nanoparticles drug delivery to melanoma. Nanomedicine 2015; 11: 769-794.
10. Zhang XH, Qiao EQ, Gao Z, Yuan HQ, Cai PF, Li XM, et al. Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model. Oncol Lett 2013; 6: 69-74.
11. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16: 5-24.
12. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-2751.
13. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118-1125.
14. Chen KG, Valencia JC, Gillet JP, Hearing VJ, Gottesman MM. Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res 2009; 22: 740-749.
15. Rockmann H, Schadendorf D. Drug resistance in human melanoma: mechanisms and therapeutic opportunities. Onkologie 2003; 26: 581-587.
16. Sarasin A, Dessen P. DNA repair pathways and human metastatic malignant melanoma. Curr Mol Med 2010; 10: 413-418.
17. Kefford RF. Adjuvant therapy of cutaneous melanoma: the interferon debate. Ann Oncol 2003; 14: 358-365.
18. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
19. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-Alpha for high-risk melanoma provide a worthwhile benefits A meta-Analysis of the randomised trials. Cancer Treat Rev 2003; 29: 241-252.
20. Busse A, Rapion J, Fusi A, Suciu S, Nonnenmacher A, Santinami M, et al. Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study). Cancer Immunol Immunother 2013; 62: 1223-1233.
21. Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012; 48: 218-225.
22. Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, et al. Metastatic melanoma -A review of current and future treatment options. Acta Derm Venereol 2015; 95: 516-524.
23. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-Tissue melanoma metastases. Br J Cancer 2003; 89: 1620-1626.
24. Guan H, Singh NP, Singh UP, Nagarkatti PS, Nagarkatti M. Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma. PLoS One 2012; 7: e35650.
25. Stones CJ, Kim JE, Joseph WR, Leung E, Marshall ES, Finlay GJ, et al. Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front Genet 2013; 4: 66.
26. Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 2008; 68: 6145-6153.
27. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-Type BRAF. Nature 2010; 464: 427-430.
28. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15: 323-332.
29. Trinh VA, Davis JE, Anderson JE, Kim KB. Dabrafenib therapy for advanced melanoma. Ann Pharmacother 2014; 48: 519-529.
30. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
31. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 1087-1095.
32. Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013; 31: 3205-3211.
33. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893-1901.
34. Lugowska I, Kosela-Paterczyk H, Kozak K, Rutkowski P. Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther 2015; 8: 2251-2259.
35. Chung C, Reilly S. Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma. Am J Health Syst Pharm 2015; 72: 101-110.
36. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-Activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-3310.
37. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
38. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-714.
39. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
40. Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, et al. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitorresistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther 2012; 11: 2704-2708.
41. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013; 31: 1767-1774.
42. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 1999; 6: 559-568.
43. Holderfield M, Nagel TE, Stuart DD. Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Br J Cancer 2014; 111: 640-645.
44. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012; 22: 668-682.
45. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, et al. V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009; 106: 4519-4524.
46. Lo RS. Receptor tyrosine kinases in cancer escape from BRAF inhibitors. Cell Res 2012; 22: 945-947.
47. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-Type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-435.
48. National Cancer Institute. FDA Approval for Trametinib. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/fda-Trametinib. [Accessed 13 March 2017].
49. Shahabi V, Whitney G, Hamid O, Schmidt H, Chasalow SD, Alaparthy S, et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother 2012; 61: 733-737.
50. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 2008; 13 (Suppl 4): 16-25.
51. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
52. Wolchok JD,Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, et al. Fouryear survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013; 24: 2174-2180.
53. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
54. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016; 39: 98-106.
55. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
56. U.S. Food & Drug Administration. Pembrolizumab. Available at: https://www. fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm412861.htm. [Accessed 13 March 2017].
57. Ascierto PA. Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma. Cancer Immunol Immunother 2015; 64: 271-274.
58. Tsai KK, Daud AI. The role of anti-PD-1/PD-L1 agents in melanoma: progress to date. Drugs 2015; 75: 563-575.
59. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.
60. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
61. Ishihara K, Saida T, Otsuka F, Yamazaki N. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol 2008; 13: 33-41.
62. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sundamaged skin. J Clin Oncol 2013; 31: 3182-3190.
63. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-Arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29: 2904-2909.
64. Kudchadkar RR, Gonzalez R, Lewis K. New targeted therapies in melanoma. Cancer Control 2013; 20: 282-288.
65. Johnson DB, Puzanov I. Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol 2015; 16: 15.
66. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118: 4014-4023.
67. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013; 14: 249-256.
68. Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res 2013; 73: 7043-7055.
69. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012; 18: 1503-1510.
70. Schuster C, Eikesdal HP, Puntervoll H, Geisler J, Geisler S, Heinrich D, et al. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One 2012; 7: e38364.
71. Jia X, Jia L. Nanoparticles improve biological functions of phthalocyanine photosensitizers used for photodynamic therapy. Curr Drug Metab 2012; 13: 1119-1122.
72. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012; 41: 2971-3010.
73. Kenjo E, Asai T, Yonenaga N, Ando H, Ishii T, Hatanaka K, et al. Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy. Biol Pharm Bull 2013; 36: 287-291.
74. Hao M, Song F, Du X, Wang G, Yang Y, Chen K, et al. Advances in targeted therapy for unresectable melanoma: new drugs and combinations. Cancer Lett 2015; 359: 1-8.
75. Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev 2005; 24: 195-222.
76. Zhu S, Lansakara PD, Li X, Cui Z. Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity. Bioconjug Chem 2012; 23: 966-980.
77. Talelli M, Iman M, Varkouhi AK, Rijcken CJ, Schiffelers RM, Etrych T, et al. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. Biomaterials 2010; 31: 7797-7804.
78. Kim TH, Lee S, Chen X. Nanotheranostics for personalized medicine. Expert Rev Mol Diagn 2013; 13: 257-269.
79. Kreiter S, Diken M, Pascolo S, Nair SK, Thielemans KM, Geall A. RNA vaccination therapy: advances in an emerging field. J Immunol Res 2016; 2016: 9703914.
80. Dany M, Nganga R, Chidiac A, Hanna E, Matar S, Elston D. Advances in immunotherapy for melanoma management. Hum Vaccin Immunother 2016; 12: 2501-2511.
81. Mroz P, Yaroslavsky A, Kharkwal GB, Hamblin MR. Cell death pathways in photodynamic therapy of cancer. Cancers (Basel) 2011; 3: 2516-2539.
82. Monge-Fuentes V, Muehlmann LA, de Azevedo RB. Perspectives on the application of nanotechnology in photodynamic therapy for the treatment of melanoma. Nano Rev 2014; 5. doi: 10.3402/nano.v5.24381.
83. Ma LW, Nielsen KP, Iani V, Moan J. A new method for photodynamic therapy of melanotic melanoma -effects of depigmentation with violet light photodynamic therapy. J Environ Pathol Toxicol Oncol 2007; 26: 165-172.
84. Soncin M, Busetti A, Biolo R, Jori G, Kwag G, Li YS, et al. Photoinactivation of amelanotic and melanotic melanoma cells sensitized by axially substituted Si-naphthalocyanines. J Photochem Photobiol B 1998; 42: 202-210.
85. Idris NM, Gnanasammandhan MK, Zhang J, Ho PC, Mahendran R, Zhang Y. In vivo photodynamic therapy using upconversion nanoparticles as remotecontrolled nanotransducers. Nat Med 2012; 18: 1580-1585.
86. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328-9337.
87. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
88. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010; 141: 583-594.